S'abonner

Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis - 08/06/20

Doi : 10.1016/j.jaci.2020.01.042 
Helen He, BS a, , Hemant Suryawanshi, PhD b, , , Pavel Morozov, PhD b, Jesús Gay-Mimbrera, PhD c, Ester Del Duca, MD a, Hyun Je Kim, MD, PhD a, Naoya Kameyama, PhD a, Yeriel Estrada, BS a, Evan Der, BS d, James G. Krueger, MD, PhD e, Juan Ruano, MD, PhD c, Thomas Tuschl, PhD b, , Emma Guttman-Yassky, MD, PhD a,
a Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 
b Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY 
e Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY 
c Department of Dermatology, Reina Sofía University Hospital, Córdoba, Spain 
d Division of Rheumatology and Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 

Corresponding author: Emma Guttman-Yassky, MD, PhD, Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Medical Center, 5 E 98th St, New York, NY 10029.Department of Dermatology and Laboratory of Inflammatory Skin DiseasesIcahn School of Medicine at Mount Sinai Medical Center5 E 98th StNew YorkNY10029∗∗Hemant Suryawanshi, PhD, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065.Laboratory of RNA Molecular Biology, The Rockefeller University1230 York AvenueNew YorkNY10065∗∗∗Thomas Tuschl, PhD, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, New York, NY, 10065.Laboratory of RNA Molecular Biology, The Rockefeller University1230 York AvenueNew YorkNY10065

Abstract

Background

Atopic dermatitis (AD) is a prevalent inflammatory skin disease with a complex pathogenesis involving immune cell and epidermal abnormalities. Despite whole tissue biopsy studies that have advanced the mechanistic understanding of AD, single cell–based molecular alterations are largely unknown.

Objective

Our aims were to construct a detailed, high-resolution atlas of cell populations and assess variability in cell composition and cell-specific gene expression in the skin of patients with AD versus in controls.

Methods

We performed single-cell RNA sequencing on skin biopsy specimens from 5 patients with AD (4 lesional samples and 5 nonlesional samples) and 7 healthy control subjects, using 10× Genomics.

Results

We created transcriptomic profiles for 39,042 AD (lesional and nonlesional) and healthy skin cells. Fibroblasts demonstrated a novel COL6A5+COL18A1+ subpopulation that was unique to lesional AD and expressed CCL2 and CCL19 cytokines. A corresponding LAMP3+ dendritic cell (DC) population that expressed the CCL19 receptor CCR7 was also unique to AD lesions, illustrating a potential role for fibroblast signaling to immune cells. The lesional AD samples were characterized by expansion of inflammatory DCs (CD1A+FCER1A+) and tissue-resident memory T cells (CD69+CD103+). The frequencies of type 2 (IL13+)/type 22 (IL22+) T cells were higher than those of type 1 (IFNG+) in lesional AD, whereas this ratio was slightly diminished in nonlesional AD and further diminished in controls.

Conclusion

AD lesions were characterized by expanded type 2/type 22 T cells and inflammatory DCs, and by a unique inflammatory fibroblast that may interact with immune cells to regulate lymphoid cell organization and type 2 inflammation.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Atopic dermatitis, single-cell RNA sequencing, fibroblasts, dendritic cells, T cells, cytokines

Abbreviations used : AD, CCL, cDC, cDC1, cDC2, CXCL, DC, DEG, ECM, FB1, FB2, FB3, IRS, KC1, KC2, KC3, LC, LEC, NC, POSTN, SC, scRNA-seq, SGC, TEWL, TPM, TRM, VEC, vSMC


Plan


 Disclosure of potential conflict of interest: J. G. Krueger is an employee of Rockefeller University and has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, BiogenIdec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to her institution) from AbbVie, Celgene, Eli Lilly, Janssen, Medimmune/Astra Zeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB and is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. The rest of the authors declare that they have no relevant conflicts of interest.


© 2020  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 145 - N° 6

P. 1615-1628 - juin 2020 Retour au numéro
Article précédent Article précédent
  • ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation
  • Juan Manuel Leyva-Castillo, Claire Galand, Shunya Mashiko, Robert Bissonnette, Alex McGurk, Steven F. Ziegler, Chen Dong, Andrew N.J. McKenzie, Marika Sarfati, Raif S. Geha
| Article suivant Article suivant
  • Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort
  • Julia L.M. Dunn, Tetsuo Shoda, Julie M. Caldwell, Ting Wen, Seema S. Aceves, Margaret H. Collins, Evan S. Dellon, Gary W. Falk, John Leung, Lisa J. Martin, Paul Menard-Katcher, Amanda K. Rudman-Spergel, Jonathan M. Spergel, Joshua B. Wechsler, Guang-Yu Yang, Glenn T. Furuta, Marc E. Rothenberg, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.